Avolynt is a clinical stage drug development company based in Research Triangle Park, North Carolina. The Company’s mission is to improve the lives of patients suffering from dysfunctions related to human metabolism. Avolynt’s team has significant discovery and development experience across the metabolic syndrome, including diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The Company’s lead programs are in phase 2 and phase 3.